课题基金 / 基金详情

SWOG 9509--PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN VS VINORELBINE--NSCLC

SWOG 9509--PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN VS VINORELBINE--NSCLC
SWOG 9509--紫杉醇加卡铂与长春瑞滨的 III 期试验--NSCLC
批准号:
6122126
负责人:
GERMAN BELTRAN
金额:
$1.12万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-07-19 至 1999-11-30

项目摘要

项目成果

GERMAN BELTRAN的其他基金

相似基金

相关文献

中文摘要
翻译
SWOG 9509:这是一项多机构III期研究。化疗对不可切除的非小细胞肺癌的影响很小。几项国际研究都有很好的证据表明,长春瑞滨/顺铂和紫杉醇/卡铂联合使用都具有活性并能提高生存率。尽管两种方案的理想给药计划仍有争议,但在一项随机试验中对它们进行了比较,以便为该疾病确定更好的标准方案。终点是生存期、无进展生存期、毒性和肿瘤反应率。预计将在当地招募约5-7名患者。
英文摘要
SWOG 9509: This is a multi-institutional phase III study. The impact of chemotherapy on nonresectable NSCLC has been marginal. There is good evidence from several international studies that both the combination of vinorelbine/cisplatin and paclitaxel/carboplatin have activity and improve survival. Although the ideal administration schedule for either regimen is still controversial they are compared in one randomized trial in order to define a better standard regimen for this disease. The endpoints are survival, progression free survival, toxicity and tumor response rate. It is anticipated that approximately 5-7 patients will be enrolled locally.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SWOG9321-STANDARD DOSE VS MYELOABLATIVE THERAPY FOR PREVIOUSLY UNTREATED MYELOMA
  • 批准号:
    6282269
  • 项目类别:
  • 资助金额:
    $1.97万
  • 财政年份:
    1997
  • 负责人:
    GERMAN BELTRAN
  • 依托单位:
SWOG 9332--ADRIAMYCIN VS TAXOL VS TAXOL PLUS ADRIAMYCIN IN BREAST CANCER
  • 批准号:
    6253137
  • 项目类别:
  • 资助金额:
    $1.16万
  • 财政年份:
    1997
  • 负责人:
    GERMAN BELTRAN
  • 依托单位:
SWOG 9410--DOXORUBICIN DOSE ESCALATION W/WO TAXOL FOR BREAST CANCER
  • 批准号:
    6253162
  • 项目类别:
  • 资助金额:
    $1.16万
  • 财政年份:
    1997
  • 负责人:
    GERMAN BELTRAN
  • 依托单位:
SWOG 9509--PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN VS VINORELBINE--NSCLC
  • 批准号:
    6298308
  • 项目类别:
  • 资助金额:
    $1.97万
  • 财政年份:
    1997
  • 负责人:
    GERMAN BELTRAN
  • 依托单位:
海外基金